# Congenital Stationary Night Blindness: Sequencing Panel

**Test Code:** MM133  
**Turnaround time:** 6 weeks  
**CPT Codes:** 81404 x1, 81479 x1

## Condition Description

Congenital stationary night blindness (CSNB) commonly refers to a non-progressive disorder with impaired night vision, reduced visual acuity, myopia, and defective dark adaptation (scotopic ERG defect) with usually normal appearance of the retina on fundus examination. CSNB may be inherited in an autosomal recessive, autosomal dominant, or X-linked manner. Please note, the **GRK1** gene is not included on the NGS panel at this time as this gene is only partially annotated in hg19. **GRK1** will be re-evaluated with the release of hg20.

### References
- OMIM
- GeneReviews

## Genes

- **CABP4**
- **CACNA1F**
- **CACNA2D4**
- **GNAT1**
- **GPR179**
- **GRM6**
- **LRIT3**
- **NYX**
- **PDE6B**
- **RBP4**
- **RDH5**
- **RHO**
- **SAG**
- **SLC24A1**
- **TRPM1**

## Indications

This test is indicated for:
- Confirmation of a clinical diagnosis of CSNB.
- Carrier testing in adults with a family history of CSNB.

## Methodology

**Next Generation Sequencing:** In-solution hybridization of all coding exons is performed on the patient's genomic DNA. Although some deep intronic regions may also be analyzed, this assay is not meant to interrogate most promoter regions, deep intronic regions, or other regulatory elements, and does not detect single or multi-exon deletions or duplications. Direct sequencing of the captured regions is performed using next generation sequencing. The patient's gene sequences are then compared to a standard reference sequence. Potentially causative variants and areas of low coverage are Sanger-sequenced. Sequence variations are classified as pathogenic, likely pathogenic, benign, likely benign, or variants of unknown significance. Variants of unknown significance may require further studies of the patient and/or family members.

### Detection

**Clinical Sensitivity:** Unknown. Pathogenic variants in the promoter region, some pathogenic variants in the introns and other regulatory element pathogenic variants cannot be detected by this analysis. Large deletions will not be detected by this analysis. Results of molecular analysis should be interpreted in the context of the patient’s clinical and/or biochemical phenotype.

**Analytical Sensitivity:** ~99%.

## Specimen Requirements

**Submit only 1 of the following specimen types**

### Type: DNA, Isolated

**Specimen Requirements:**
- Microtainer 8µg
- Isolation using the Perkin Elmer™ Chemagen™ Automated Extraction method or Qiagen™ Puregene kit for DNA extraction is recommended.

**Specimen Collection and Shipping:**
- Refrigerate until time of shipment in 100 ng/µL in TE buffer. Ship sample at room temperature with overnight delivery.

### Type: Saliva

**Specimen Requirements:**
- Orangene™ Saliva Collection Kit
- Orangene™ Saliva Collection Kit used according to manufacturer instructions. Please contact EGL for a Saliva Collection Kit for patients that cannot provide a blood sample.

**Specimen Collection and Shipping:**
- Please do not refrigerate or freeze saliva sample. Please store and ship at room temperature.
Type: Whole Blood (EDTA)

Specimen Requirements:
EDTA (Purple Top)
Infants and Young Children (2 years of age to 10 years old): 3-5 ml
Older Children & Adults: 5-10 ml
Autopsy: 2-3 ml unclotted cord or cardiac blood

Specimen Collection and Shipping:
Ship sample at room temperature for receipt at EGL within 24 hours of collection. Do not refrigerate or freeze.

Special Instructions

Please include fundus photographs, electroretinogram (ERG) findings, visual field findings, and visual acuity, if available, for expert review and clinical correlation with test results.

Related Tests

- Eye Disorders: Comprehensive Sequencing and Deletion/Duplication Panels.